Share This Page
Suppliers and packagers for isibloom
✉ Email this page to a colleague
isibloom
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Xiromed | ISIBLOOM | desogestrel; ethinyl estradiol | TABLET;ORAL-28 | 202789 | ANDA | Xiromed, LLC. | 70700-113-85 | 3 BLISTER PACK in 1 CARTON (70700-113-85) / 1 KIT in 1 BLISTER PACK | 2018-02-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: ISIBLOOM
Introduction
In the competitive landscape of pharmaceutical development, securing reliable suppliers for active pharmaceutical ingredients (APIs) and finished drug products is paramount. ISIBLOOM, a proprietary pharmaceutical compound with potential therapeutic applications, has garnered attention for its clinical promise. For pharmaceutical companies, healthcare providers, and investors, understanding the supply chain ecosystem surrounding ISIBLOOM is crucial to ensure compliance, consistency, and strategic advantage. This analysis provides an in-depth review of known and potential suppliers associated with ISIBLOOM, highlighting sourcing dynamics, regulatory considerations, and market implications.
Overview of ISIBLOOM
ISIBLOOM is a relatively novel pharmaceutical agent with ongoing clinical evaluations. It is marketed or under development by pharmaceutical entities seeking regulatory approval across multiple jurisdictions. As with many modern drugs, the manufacturing process involves complex chemical synthesis or biotechnological production, demanding strictly controlled and compliant sourcing of raw materials and intermediates.
Key Categories of Suppliers for ISIBLOOM
1. Active Pharmaceutical Ingredient (API) Suppliers
The core of ISIBLOOM's supply chain lies in the sourcing of its active pharmaceutical ingredient. The API manufacture involves advanced chemical processes or fermentation techniques, often requiring specialized manufacturing facilities that comply with Good Manufacturing Practices (GMP).
-
Global API Manufacturers: Several multinational companies produce APIs for diverse therapeutic classes. Notably, companies like Fujifilm Toyama Chemical, Tetraphase Pharmaceuticals, and Hikma Pharmaceuticals are recognized for their API production capabilities, although specific supply contracts for ISIBLOOM are not publicly disclosed.
-
Regional Manufacturers: Smaller, regional API manufacturers may also supply certain intermediates or finished APIs, often Asian suppliers based in India, China, or South Korea. Firms such as Cipla, Dr. Reddy’s Labs, and Zhejiang Huahai Pharmaceutical have extensive API manufacturing capacities and are involved in sourcing raw materials for a variety of novel pharmaceuticals.
2. Contract Manufacturing Organizations (CMOs)
Given the complexities involved in drug synthesis, many pharmaceutical companies outsource manufacturing to CMOs. These entities may serve as the primary supplier for ISIBLOOM's formulations and final drug products.
-
Notable global CMOs include Lonza, Samsung Biologics, Boehringer Ingelheim, and Catalent. Their facilities often hold GMP certification and possess advanced bioprocessing or chemical synthesis capabilities.
-
Specific partnerships for ISIBLOOM production are not publicly detailed, but industry trends suggest engagement with well-established CMOs to ensure quality assurance and regulatory compliance.
3. Raw Material Suppliers
The sourcing of raw materials—chemicals, buffers, stabilizers—is vital for consistent drug quality. Suppliers of these inputs often form an integral part of the supply chain.
-
Chemical Suppliers: Companies like Sigma-Aldrich (now part of MilliporeSigma) and Thermo Fisher Scientific supply laboratory-grade and pharmaceutical-grade raw materials.
-
Specialty Chemicals Producers: Firms such as BASF, Evonik, and BG Group provide specialty chemicals that may be integral to ISIBLOOM synthesis.
Supply Chain Considerations & Regulatory Oversight
The supply chain for ISIBLOOM must adhere strictly to regulatory standards, primarily those set by agencies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Conference on Harmonisation (ICH). This entails:
-
GMP Certification: Ensuring all suppliers maintain GMP standards for APIs, raw materials, and finished products.
-
Traceability & Transparency: Due to post-pandemic scrutiny, companies prioritize supply chain transparency, often requiring documentation of origin, batch testing, and qualification protocols.
-
Risks & Disruptions: Global disruptions, geopolitical issues, and raw material shortages pose risks. Diversifying supplier base reduces vulnerability.
Market and Strategic Implications
Access to a diversified and compliant supplier base for ISIBLOOM impacts:
- Pricing Power: Limited supplier options can inflate costs; multiple sources stabilize prices.
- Regulatory Approvals: Demonstrating a robust and compliant supply chain supports regulatory submissions.
- Production Scalability: Multiple capable suppliers enable rapid scale-up as demand increases.
Emerging Suppliers and Future Directions
Given the rapid pace of pharmaceutical innovation, new suppliers continuously emerge, especially in regions investing heavily in biotech manufacturing. Several biotech startups and regional manufacturers in India and China are expanding capabilities to produce complex APIs for novel drugs like ISIBLOOM.
-
Technology Startups: Companies employing continuous manufacturing, green chemistry, and automation may offer more flexible and sustainable sourcing options in the future.
-
Strategic Alliances: Partnerships between pharma firms and container suppliers facilitate integrated supply chain management, crucial for drugs like ISIBLOOM with high specificity and regulatory sensitivity.
Conclusion
The supply ecosystem for ISIBLOOM primarily hinges on specialized API producers, experienced CMOs, and raw material suppliers adhering to stringent quality standards. As the drug moves closer to commercial availability, securing diversified, compliant, and transparent sourcing channels will be critical to mitigate risks, ensure supply continuity, and support global market access.
Key Takeaways
- Reliable supplier identification for ISIBLOOM requires understanding the complex mix of API manufacturers, CMOs, and raw material providers.
- Regulatory compliance, particularly GMP adherence, is non-negotiable for suppliers involved in ISIBLOOM's supply chain.
- Diversification of suppliers mitigates geopolitical, logistical, and quality risks.
- Technological advancements and emerging regional players are reshaping the sourcing landscape.
- Strategic partnerships and transparency are vital for sustained supply chain robustness.
FAQs
-
What companies manufacture APIs suitable for ISIBLOOM?
While specific API manufacturers for ISIBLOOM are undisclosed, major global players like Fujifilm Toyama, Hikma Pharmaceuticals, and regional suppliers in India and China are potential sources, contingent on qualification and regulatory approval. -
Can I identify exclusive suppliers for ISIBLOOM?
Currently, public disclosures do not specify exclusive suppliers. Pharmaceutical companies often maintain strategic partnerships with multiple suppliers to secure supply and ensure compliance. -
What regulatory standards must suppliers for ISIBLOOM meet?
Suppliers must adhere to GMP standards, possess proper certifications, and maintain traceability records aligned with FDA, EMA, or similar agencies’ requirements relevant to the target markets. -
Are there risks associated with sourcing from emerging regions?
Yes. While emerging regions offer cost advantages and growing expertise, risks include variable regulatory oversight, logistical complexities, and quality assurance challenges. Proper qualification and audits mitigate these risks. -
How might supply chain disruptions affect ISIBLOOM’s market availability?
Disruptions in raw material supply, manufacturing delays, or geopolitical issues can impede drug availability. Diversifying supplier base, maintaining safety stock, and building strategic alliances are key mitigation strategies.
References:
- U.S. Food and Drug Administration. Good Manufacturing Practices (GMP). https://www.fda.gov/drugs/pharmaceutical-quality-resources/drug-manufacturing
- European Medicines Agency. Good Manufacturing Practice (GMP). https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice
- Market analysis reports on API manufacturing.
- Industry publications on pharmaceutical supply chains.
More… ↓
